Every material Form 8-K Pelthos Therapeutics Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pelthos Therapeutics agreed on October 30, 2026 to merge with Castle Creek Biosciences in a two-step merger, with Castle Creek becoming a wholly owned subsidiary. Castle Creek holders would receive 5,200,000 Pelthos shares at closing, plus contingent shares, milestone payments and priority review voucher proceeds, and would own about 32.5% of Pelthos on a fully diluted basis before the PIPE financing. Closing requires stockholder approvals from both companies and is expected by the end of the first quarter of 2027.
5,200,000 Pelthos common shares issued to Castle Creek holders at closing, about 32.5% of fully diluted shares before the PIPE financing
Up to 5,800,000 additional Pelthos shares if FDA approval of D-Fi is received on or before March 31, 2036
Up to $300 million in milestone payments tied to D-Fi clinical, commercial and net sales targets, plus 80% of any priority review voucher sale proceeds
Either party may terminate if the First Merger is not completed by February 1, 2027, subject to extension to March 31, 2027 in certain circumstances
At its September 29, 2026 annual meeting, Pelthos Therapeutics stockholders approved a new 2026 Equity Incentive Plan that replaces the 2023 plan, and re-elected all eight director nominees. Stockholders also ratified Grant Thornton LLP as the auditor for fiscal 2026. The filing reports votes only and does not disclose financial results.
Stockholders approved the 2026 Equity Incentive Plan, effective immediately, with 2,698,543 for and 187,365 against.
All eight director nominees were elected to serve until the 2027 annual meeting.
Grant Thornton LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
Quorum was met with 3,396,094 votes, or 70.0% of voting power as of the August 4, 2026 record date.
Pelthos reported second quarter 2026 net product revenue for Zelsuvmi of $15.4 million, up 45% from the first quarter, and a net loss of $23.4 million, narrower than the restated $25.1 million loss for the first quarter. The company also said its previously issued first quarter 2026 financial statements should no longer be relied upon and should be restated, and its stockholders' equity was a deficit of $(1.5) million at June 30, 2026.
Q2 2026 net product revenue was $15.4 million, up from $10.7 million in Q1 2026, a 45% increase
Q2 2026 net loss was $(23.4) million versus a restated $(25.1) million in Q1 2026; Adjusted EBITDA was $(5.7) million versus $(8.0) million
Q1 2026 financial statements should no longer be relied upon, per a separate Item 4.02 filing referenced in this 8-K
Total stockholders' equity was $(1.5) million at June 30, 2026, compared with $38.9 million at December 31, 2025; cash was $24.2 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pelthos Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →